Prostate-specific membrane antigen (PSMA) is highly expressed on the membrane of most
prostate cancer cells and to a lesser extent in normal tissues. Many vectors targeting this …

Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

The validation of prostate specific membrane antigen (PSMA) as a molecular target in
metastatic castration-resistant prostate cancer has stimulated the development of multiple …

Context Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …

Simple Summary One of the most frequently diagnosed cancer in men is adenocarcinoma of
the prostate. Once the disease is metastatic, only very limited treatment options are …

Metastatic prostate cancer continues to be an incurable disease. Despite all the novel
therapies approved in the past two decades, overall patient outcomes remain relatively poor …

Simple Summary Radioligand therapy plays a crucial role in the management of prostate
cancer patients, for whom despite all available treatments, natural progression is almost …

Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …

Although prostate cancer is the type of cancer most commonly survived by men in the United
States, it remains the second most common cause of death from cancer, largely owing to …

Abstract Purpose of Review Prostate-specific membrane antigen (PSMA)-targeted
radionuclide therapy (TRT) is a promising investigational treatment for metastatic castration …